The Danish Medicines Agency has completed its review of an application for general reimbursement for Brilique®. The product has been granted general reimbursement.
Together with acetylsalicylic acid, Brilique® is authorised to prevent atherothrombotic events (e.g. blood clots) in adult patients with acute myocardial infarction (e.g. heart attack).
When we compare Brilique® with clopidogrel, we assess that, on the basis of a health economic analysis, the price of the medicine is commensurate with its therapeutic value.
The reimbursement status of Brilique® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.
Please find the Reimbursement Committee recommendation and the Danish Medicines Agency’s decision in the factbox to the right (in Danish only).